Results 241 to 250 of about 1,259,204 (342)

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The development and the genetic diseases of the ciliary body. [PDF]

Cell Insight
Li B, Xie T, Nawy S, Shen Y.
europepmc   +1 more source

Interactive influence of infectious disease and genetic diversity in natural populations

, 1988
Stephen J. O’Brien, James F. Evermann
openalex   +1 more source

Vaccines '88: New Chemicals and Genetic Approaches to Vaccination. Prevention of AIDS and other viral, bacterial and parasitic diseases. Edited by H. Ginsberg, F. Brown, R. A. Lerner and R. M. Channock. New York: Cold Spring Harbor Labortory. 1988. 396 pages. Paper $9500. ISBN 0 87969 210 X. [PDF]

, 1989
Robert G. Ridley
openalex   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Editorial: The clinical utility of long read sequencing to improve diagnostic yield and uncover biological mechanisms in rare disease

Frontiers in Genetics
Lidia Larizza, Christopher M. Watson, Christopher M. Watson, Madelyn A. Gillentine, Palma Finelli, Palma Finelli   +5 more
doaj   +1 more source

Proteome-scale prediction of molecular mechanisms underlying dominant genetic diseases. [PDF]

PLoS One
Badonyi M, Marsh JA.
europepmc   +1 more source

MIF as an oncogenic driver of low‐heterogeneity melanomas

Molecular Oncology, EarlyView.
Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran, Gabriela Athziri Sánchez‐Zuno, Rajan P. Kulkarni, Harriet M. Kluger, Richard Bucala   +4 more
wiley   +1 more source

Screening of Living Kidney Donors for Genetic Diseases: Commentary. [PDF]

Kidney360
Steiner RW.
europepmc   +1 more source

Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group

, 1989
Y Morishima, Y Morishita, Masashi Tanimoto, R Ohno, Hajime Saito, Keizo Horibe, Nobuyuki Hamajima, Kensuke Naito, K Yamada, S Yokomaku   +9 more
openalex   +1 more source